新型抗哮喘药物-动脉网

Novel anti-asthma drug

D-Pharm 等信源发布 2025-03-24 13:52



可切换为仅中文







LMU scientist Olivia Merkel researches

LMU科学家奥利维亚·默克尔研究

nanocarriers

纳米载体

for the targeted delivery of drugs to their site of action. Now the company she co-founded, RNhale, has been awarded a lucrative EU grant to bring a new anti-

用于将药物靶向递送至其作用部位。现在，她共同创立的公司 RNhale 已获得了一笔丰厚的欧盟拨款，用于推出一种新的抗输卵

asthma

哮喘

therapy to clinical readiness. The company name describes the envisioned product in a nutshell: RNhale – that is,

治疗到临床应用。公司名称简要描述了预期的产品：RNhale——即，

RNA therapeutics

RNA治疗学

to inhale. Now the young Munich-based company has been awarded a Transition grant of 2.5 million euros by the European Innovation Council (EIC) to bring such a novel anti-asthma drug to clinical practice.

吸入。现在，这家总部位于慕尼黑的年轻公司获得了欧洲创新委员会（EIC）颁发的250万欧元的过渡补助金，以将这种新型抗哮喘药物引入临床实践。

CEO Benjamin Winkeljann is part of the founder team.

首席执行官本杰明·温克尔扬是创始团队的一员。

The company RNhale is an LMU spin-off: Olivia Merkel, Chair Professor of Drug Delivery, and her team have built up the requisite know-how over many years. The pharmaceutical researcher investigates novel nanocarrier systems capable of delivering drugs to specific sites of action in the human body. Her main research focus is on the therapeutic application of short sections of RNA that can silence genes involved in pathogenesis in certain cell types..

RNhale公司是LMU的衍生公司：药物递送领域的教席教授Olivia Merkel及其团队经过多年积累，建立了必要的专业知识。这位制药学研究人员探索能够将药物递送到人体特定作用部位的新型纳米载体系统。她的主要研究重点在于短链RNA的治疗应用，这些RNA可以沉默某些细胞类型中与疾病发生相关的基因。

On this basis, Merkel and her team developed approaches for new anti-asthma therapies, with funding from sources such as a multi-million euro Starting Grant from the European Research Council (ERC). The researchers packed specific so-called siRNA into nanocarriers that can be stabilized by means of spray drying and processed into an inhalable dry powder..

在此基础上，默克尔和她的团队开发了新的抗哮喘疗法，资金来源包括欧洲研究委员会（ERC）提供的数百万欧元的启动基金。研究人员将特定的所谓小干扰RNA（siRNA）装入纳米载体中，这些载体可以通过喷雾干燥来稳定，并加工成可吸入的干粉。

To enable Merkel to put such therapeutics to the test, she was awarded a Proof of Concept Grant by the ERC. Following the receipt of additional funding from LMU’s Knowledge Transfer Fund, the conditions were right to found the spin-off RNhale, for which Merkel acts as scientific advisor. The founder team includes various colleagues at LMU, including the CEO Benjamin Winkeljann..

为了使默克尔能够测试这样的治疗方法，她获得了ERC颁发的概念验证资助。在获得LMU知识转移基金的额外资助后，成立衍生公司RNhale的条件已经成熟，默克尔担任该公司的科学顾问。创始团队包括LMU的多位同事，其中包括首席执行官本杰明·温克尔扬。

Logical next link in Brussels funding chain

布鲁塞尔资金链中的逻辑下一环

The new EIC grant is the logical next link in this funding chain from Brussels. RNhale will use the grant to prepare the technology for clinical studies and drive forward the development of the business for market release. This includes preparing the requisite preclinical trials.

新的EIC拨款是来自布鲁塞尔的这一资助链中的下一个合理环节。RNhale将利用这笔拨款为临床研究准备技术，并推动业务发展以实现市场发布。这包括准备必要的临床前试验。

As an initial application, the company plans to develop a drug to reduce expression of the cytokine TSLP in the respiratory tract, which occurs in patients with allergic asthma. Through this work, RNhale ultimately hopes not only to bring a highly effective anti-asthma therapeutic to market, but also to create a platform that can be used to develop drugs to treat other respiratory conditions..

作为初步应用，该公司计划开发一种药物，以减少过敏性哮喘患者呼吸道中细胞因子 TSLP 的表达。通过这项工作，RNhale 最终希望不仅能够推出一种高效的抗哮喘治疗药物，还能创建一个可用于开发治疗其他呼吸系统疾病药物的平台。

https://www.bionity.com/en/news/1185860/novel-anti-asthma-drug.html

https://www.bionity.com/zh/news/1185860/新型抗哮喘药物.html

Signs of developing asthma are evident in the first year of life

生命的第一年中就可以看到哮喘发展的迹象。

A new way of looking at chronic illness

慢性疾病的新视角

Read news

读新闻